MedImmune Recalls 4.7 Million Doses of H1N1 Vaccine Because of Drop in Potency
MedImmune, a division of AstraZeneca (London, UK), yesterday recalled 13 lots (4.7 million doses) of its nasal spray H1N1 (swine) flu vaccine, because of a drop in potency.
MedImmune, a division of AstraZeneca (London, UK), yesterday recalled 13 lots (4.7 million doses) of its nasal spray H1N1 (swine) flu vaccine, because of a drop in potency.
The company detected the slight decline in potency as part of its routine stability testing, and notified the Centers for Disease Control and Prevention (CDC) and the US Food and Drug Administration on December 16 and 21. The vaccine in these lots is still expected to be effective in stimulating immunity, however, so people who received vaccinations from those lots do not need to be re-vaccinated.
Most of the affected doses were shipped in the first few weeks of H1N1 vaccination, when the vaccine's potency was still at or above the specification limit.
Sanofi-Aventis SA (Paris, France) recalled 800,000 doses of its pediatric H1N1 flu vaccine on December 15, also because of a drop in potency detected during stability studies.
Previous coverage:
Sanofi Recalls 800,000 Doses of H1N1 (Swine) Flu Vaccine for Children
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
